{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:34:22Z","timestamp":1791592462763,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The success of drug-coated balloon (DCB) therapy for de novo coronary lesions relies on optimal lesion preparation. However, evidence supporting the use of cutting balloons (CBs) for lesion preparation in DCB-only strategies remains limited. The NATURE trial assessed the effectiveness of CB compared with standard balloon (SB) predilatation in achieving optimal lesion preparation for a DCB-only strategy. The NATURE trial was a prospective, multicentre, randomised study conducted at 19 Japanese centres. Patients with de novo coronary lesions suitable for a DCB-only strategy were randomised (1:1) to lesion preparation with CB or SB. Post-predilatation assessment included coronary angiography, intravascular ultrasound (IVUS), and fractional flow reserve (FFR). The primary endpoint was optimal lesion preparation, defined as the simultaneous presence of: (1) no flow-limiting dissection, (2) residual diameter stenosis\u2009\u2264\u200930% by quantitative coronary angiography, and (3) FFR\u2009&gt;\u20090.80. Among 201 patients included in the intention-to-treat population, optimal lesion preparation was achieved in 35.6% of the CB group and 30.0% of the SB group (adjusted risk ratio 1.19, 95% confidence interval 0.87\u20131.65; p\u2009=\u20090.28). Avoidance of flow-limiting dissection was high in both groups (98.0% vs 97.0%). CB predilatation resulted in lower residual diameter stenosis (30.8\u2009\u00b1\u200911.8% vs 34.5\u2009\u00b1\u200913.3%; p\u2009=\u20090.04) and less acute recoil (1.18\u2009\u00b1\u20090.36 vs 1.31\u2009\u00b1\u20090.50\u00a0mm; p\u2009=\u20090.03). Trends towards larger lumen dimensions on IVUS were also observed with CB. In patients undergoing DCB-only PCI for de novo coronary lesions, CB predilatation provided modest angiographic advantages compared with SB but did not significantly increase the rate of optimal lesion preparation. Optimal lesion preparation is essential for successful drug-coated balloon (DCB) therapy because DCBs do not provide mechanical scaffolding to maintain vessel patency. In this multicentre randomised trial, cutting balloon predilatation resulted in greater acute luminal expansion and less recoil than standard balloon predilatation, although it did not significantly increase the overall rate of optimal lesion preparation defined by angiographic and physiological criteria. These findings suggest that cutting balloons may offer modest mechanical advantages during lesion preparation in DCB-only PCI. However, the clinical significance of these acute angiographic advantages requires confirmation in larger trials and through longer-term follow-up.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>This central illustration summarises the study design, procedural workflow, and key findings of the NATURE trial. Patients with de novo coronary lesions were randomised to lesion preparation with a cutting balloon or a standard balloon before a drug-coated balloon (DCB)\u2013only strategy. Multimodality assessments using quantitative coronary angiography (QCA) and fractional flow reserve (FFR) were performed serially from pre\u2013percutaneous coronary intervention through post-predilatation and post-DCB treatment, and intravascular ultrasound (IVUS) was performed after predilatation. The primary endpoint\u2014achievement of optimal lesion preparation defined as the absence of flow-limiting dissection, residual diameter stenosis\u2009\u2264\u200930%, and FFR\u2009&gt;\u20090.80\u2014was achieved in 35.6% of patients in the cutting balloon group and 30.0% in the standard balloon group. Cutting balloon use was associated with less aggressive predilatation and more favorable acute angiographic outcomes, including greater minimum lumen diameter and lower acute recoil, whereas the overall achievement of optimal lesion preparation and the DCB-only strategy without bailout stenting was comparable between the groups. DCB\u2009=\u2009drug-coated balloon; FFR\u2009=\u2009fractional flow reserve; IVUS\u2009=\u2009intravascular ultrasound; MLD\u2009=\u2009minimum lumen diameter; MLA\u2009=\u2009minimum lumen area; PCI\u2009=\u2009percutaneous coronary intervention; QCA\u2009=\u2009quantitative coronary angiography.<\/jats:p>","DOI":"10.1007\/s12928-026-01330-x","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:57:37Z","timestamp":1787680657000},"page":"1053-1067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cutting vs standard balloon for lesion preparation in drug-coated balloon-only PCI: the NATURE randomised trial"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5733-3381","authenticated-orcid":false,"given":"Taku","family":"Asano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Kogame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Sawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisuke","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Osakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Nanasato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ashikaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunori","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehiro","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaku","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kozuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the NATURE trial investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"9","key":"1330_CR1","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jacc.2019.12.046","volume":"75","author":"C Yerasi","year":"2020","unstructured":"Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, et al. Drug-coated balloon for de novo coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(9):1061\u201373.","journal-title":"J Am Coll Cardiol"},{"issue":"10150","key":"1330_CR2","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(18)31719-7","volume":"392","author":"RV Jeger","year":"2018","unstructured":"Jeger RV, Farah A, Ohlow MA, Mangner N, Mobius-Winkler S, Leibundgut G, et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018;392(10150):849\u201356.","journal-title":"Lancet"},{"issue":"10261","key":"1330_CR3","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/S0140-6736(20)32173-5","volume":"396","author":"RV Jeger","year":"2020","unstructured":"Jeger RV, Farah A, Ohlow MA, Mangner N, Mobius-Winkler S, Weilenmann D, et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet. 2020;396(10261):1504\u201310.","journal-title":"Lancet"},{"issue":"10457","key":"1330_CR4","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S0140-6736(24)01594-0","volume":"404","author":"C Gao","year":"2024","unstructured":"Gao C, He X, Ouyang F, Zhang Z, Shen G, Wu M, et al. Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of patients with de novo coronary artery lesions (REC-CAGEFREE I): an open-label, randomised, non-inferiority trial. Lancet. 2024;404(10457):1040\u201350.","journal-title":"Lancet"},{"key":"1330_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ahj.2023.01.007","volume":"258","author":"C Spaulding","year":"2023","unstructured":"Spaulding C, Krackhardt F, Bogaerts K, Urban P, Meis S, Morice MC, et al. Comparing a strategy of sirolimus-eluting balloon treatment to drug-eluting stent implantation in de novo coronary lesions in all-comers: design and rationale of the SELUTION DeNovo trial. Am Heart J. 2023;258:77\u201384.","journal-title":"Am Heart J"},{"key":"1330_CR6","unstructured":"Christian Spaulding SE, Florian Krackhardt, Kris Bogaerts, Philip Urban One-year results of the SELUTION DeNovo trial comparing a strategy of PCI with a sirolimus-eluting balloon and provisional stenting versus systematic DES implantation to treat de novo coronary lesions. In: TCT2025. Moscone Center, San Francisco; 2025."},{"key":"1330_CR7","doi-asserted-by":"crossref","unstructured":"Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, Alfonso F, Latib A, Ong PJ, Rissanen TT, Saucedo J, Scheller B, Kleber FX, International DCBCG. Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC Cardiovasc Interv. 2020;13(12):1391\u20131402.","DOI":"10.1016\/j.jcin.2020.02.043"},{"issue":"3","key":"1330_CR8","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4244\/EIJV6I3A66","volume":"6","author":"Y Ozaki","year":"2010","unstructured":"Ozaki Y, Lemos PA, Yamaguchi T, Suzuki T, Nakamura M, Ismail TF, et al. A quantitative coronary angiography-matched comparison between a prospective randomised multicentre cutting balloon angioplasty and bare metal stent trial (REDUCE III) and the Rapamycin-Eluting Stent Evaluation At Rotterdam Cardiology Hospital (RESEARCH) study. EuroIntervention. 2010;6(3):400\u20136.","journal-title":"EuroIntervention"},{"issue":"7","key":"1330_CR9","first-page":"1656","volume":"105","author":"M Shiozaki","year":"2025","unstructured":"Shiozaki M, Torii S, Sato Y, Aihara K, Matsumoto Y, Nakamura N, et al. Enhanced drug effect with cutting balloon followed by drug coated balloon in a rabbit model. Catheter Cardiovasc Interv. 2025;105(7):1656\u201363.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"13","key":"1330_CR10","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.jcin.2017.04.024","volume":"10","author":"S Kufner","year":"2017","unstructured":"Kufner S, Joner M, Schneider S, Tolg R, Zrenner B, Repp J, et al. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial. JACC Cardiovasc Interv. 2017;10(13):1332\u201340.","journal-title":"JACC Cardiovasc Interv"},{"key":"1330_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2025.03.009","author":"M Ono","year":"2025","unstructured":"Ono M, Asano T, Noguchi M, Kogame N, Iijima R, Osakada K, et al. Cutting balloon versus standard balloon for lesion preparation of drug-coated balloon treatment in de-novo coronary artery lesions: rationale and design of the randomized NATURE trial. Cardiovasc Revasc Med. 2025. https:\/\/doi.org\/10.1016\/j.carrev.2025.03.009.","journal-title":"Cardiovasc Revasc Med"},{"issue":"1","key":"1330_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1253\/circrep.CR-20-0070","volume":"3","author":"X Zhu","year":"2020","unstructured":"Zhu X, Umezu M, Iwasaki K. Finite element analysis of the cutting balloon with an adequate balloon-to-artery ratio for fracturing calcification while preventing perforation. Circ Rep. 2020;3(1):1\u20138.","journal-title":"Circ Rep"},{"issue":"2","key":"1330_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s12928-020-00653-7","volume":"35","author":"N Suzuki","year":"2020","unstructured":"Suzuki N, Asano T, Nakazawa G, Aoki J, Tanabe K, Hibi K, et al. Clinical expert consensus document on quantitative coronary angiography from the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovasc Interv Ther. 2020;35(2):105\u201316.","journal-title":"Cardiovasc Interv Ther"},{"key":"1330_CR14","first-page":"757","volume-title":"Qualitative and quantitative coronary angiography","author":"J Popma","year":"2012","unstructured":"Popma J, Almonacid A, Burke D. Qualitative and quantitative coronary angiography. 2012. p. 757\u201375."},{"key":"1330_CR15","doi-asserted-by":"crossref","unstructured":"Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, Pinto FJ, Rosenfield K, Siegel RJ, Tuzcu EM, Yock PG. American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2001;37(5):1478\u201392.","DOI":"10.1016\/S0735-1097(01)01175-5"},{"issue":"1","key":"1330_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12928-023-00957-4","volume":"39","author":"Y Saito","year":"2024","unstructured":"Saito Y, Kobayashi Y, Fujii K, Sonoda S, Tsujita K, Hibi K, et al. CVIT 2023 clinical expert consensus document on intravascular ultrasound. Cardiovasc Interv Ther. 2024;39(1):1\u201314.","journal-title":"Cardiovasc Interv Ther"},{"issue":"15","key":"1330_CR17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jacc.2025.07.049","volume":"86","author":"S Fezzi","year":"2025","unstructured":"Fezzi S, Serruys PW, Cortese B, Scheller B, Alfonso F, Jeger R, et al. Indications for use of drug-coated balloons in coronary intervention: academic research consortium position statement. J Am Coll Cardiol. 2025;86(15):1170\u2013202.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"1330_CR18","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jacc.2013.08.720","volume":"62","author":"ID Moussa","year":"2013","unstructured":"Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013;62(17):1563\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1330_CR19","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/S0735-1097(99)00450-7","volume":"34","author":"RA van Liebergen","year":"1999","unstructured":"van Liebergen RA, Piek JJ, Koch KT, Peters RJ, de Winter RJ, Schotborgh CE, et al. Hyperemic coronary flow after optimized intravascular ultrasound-guided balloon angioplasty and stent implantation. J Am Coll Cardiol. 1999;34(7):1899\u2013906.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1330_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1001\/jamainternmed.2017.7821","volume":"178","author":"H Zhang","year":"2018","unstructured":"Zhang H, Mu L, Hu S, Nallamothu BK, Lansky AJ, Xu B, et al. Comparison of physician visual assessment with quantitative coronary angiography in assessment of stenosis severity in China. JAMA Intern Med. 2018;178(2):239\u201347.","journal-title":"JAMA Intern Med"},{"key":"1330_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2016.10.014","volume":"184","author":"R Shah","year":"2017","unstructured":"Shah R, Yow E, Jones WS, Kohl LP 3rd, Kosinski AS, Hoffmann U, et al. Comparison of visual assessment of coronary stenosis with independent quantitative coronary angiography: findings from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. Am Heart J. 2017;184:1\u20139.","journal-title":"Am Heart J"},{"issue":"25","key":"1330_CR22","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1016\/j.jacc.2009.11.096","volume":"55","author":"PA Tonino","year":"2010","unstructured":"Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010;55(25):2816\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1330_CR23","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s10554-012-0016-6","volume":"28","author":"S Tu","year":"2012","unstructured":"Tu S, Xu L, Ligthart J, Xu B, Witberg K, Sun Z, et al. In vivo comparison of arterial lumen dimensions assessed by co-registered three-dimensional (3D) quantitative coronary angiography, intravascular ultrasound and optical coherence tomography. Int J Cardiovasc Imaging. 2012;28(6):1315\u201327.","journal-title":"Int J Cardiovasc Imaging"},{"key":"1330_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijcard.2020.07.028","volume":"321","author":"T Yamamoto","year":"2020","unstructured":"Yamamoto T, Sawada T, Uzu K, Takaya T, Kawai H, Yasaka Y. Possible mechanism of late lumen enlargement after treatment for de novo coronary lesions with drug-coated balloon. Int J Cardiol. 2020;321:30\u20137.","journal-title":"Int J Cardiol"},{"issue":"1","key":"1330_CR25","first-page":"E35","volume":"98","author":"K Sogabe","year":"2021","unstructured":"Sogabe K, Koide M, Fukui K, Kato Y, Kitajima H, Akabame S, et al. Optical coherence tomography analysis of late lumen enlargement after paclitaxel-coated balloon angioplasty for de-novo coronary artery disease. Catheter Cardiovasc Interv. 2021;98(1):E35\u201342.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"4","key":"1330_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12928-019-00571-3","volume":"34","author":"A Funatsu","year":"2019","unstructured":"Funatsu A, Kobayashi T, Mizobuchi M, Nakamura S. Clinical and angiographic outcomes of coronary dissection after paclitaxel-coated balloon angioplasty for small vessel coronary artery disease. Cardiovasc Interv Ther. 2019;34(4):317\u201324.","journal-title":"Cardiovasc Interv Ther"},{"issue":"13","key":"1330_CR27","doi-asserted-by":"publisher","first-page":"e818","DOI":"10.4244\/EIJ-D-23-01006","volume":"20","author":"T Lee","year":"2024","unstructured":"Lee T, Ashikaga T, Nozato T, Nagata Y, Kaneko M, Miyazaki R, et al. Predictors of target lesion failure after percutaneous coronary intervention with a drug-coated balloon for de novo lesions. EuroIntervention. 2024;20(13):e818\u201325.","journal-title":"EuroIntervention"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-026-01330-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12928-026-01330-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-026-01330-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:14:56Z","timestamp":1789582496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12928-026-01330-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1007\/s12928-026-01330-x","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T Asano reports personal fees from Boston Scientific Japan, Philips Japan, and Nipro Corporation; M Sawano reports personal fees from Boehringer Ingelheim and Abbott Medical, and research funding from Polybio, Pfizer, and Novartis; T Ishihara reports personal fees from Kaneka and Nipro Corporation; K Ando reports personal fees from Japan Lifeline, Abbott Medical Japan, Medtronic Japan, BIOTRONIK Japan, and Novartis Pharma; M Nanasato reports personal fees from Abbott Medical Japan and Boston Scientific Japan; K Tanabe reports personal fees from Abbott Medical Japan, Boston Scientific Japan, Kaneka Corporation, and Edwards Lifesciences Japan; T Muramatsu reports personal fees from Boston Scientific Japan; A Okamura reports personal fees from Boston Scientific Japan, Abbott Medical Japan, Kaneka, Nipro Corporation, and Terumo; Y Kinoshita reports personal fees from Boston Scientific; K Hibi reports research funding from Boston Scientific; G Nakazawa reports personal fees from Abbott Medical, Boston Scientific Japan, Terumo, Shockwave Medical Japan, HeartFlow, Medtronic, and OrbusNeich; M Nakamura reports personal fees from Terumo and Boston Scientific; K Kozuma reports personal fees from Boston Scientific, Abbott Medical, and Medtronic, and research funding from Abbott Medical; All other co-authors have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}